Healthcare Global Enterprises Ltd.
NSE: HCG · Hospital
Snapshot
Unlock Healthcare Global Enterprises Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
HealthCare Global Enterprises Limited is a specialised healthcare provider primarily focused on comprehensive cancer care, including diagnosis, radiation therapy, medical oncology, and surgery. The company also operates fertility clinics under the Milann brand and maintains a network of multi-specialty hospitals and diagnostic centres across India and Africa.
Business Model
The company generates revenue through the provision of specialised medical services, including oncology treatments, fertility procedures, and multi-specialty hospital care. It operates through a combination of owned centres, day-care facilities, and management contracts for hospital operations.
- Cancer Centres:23
- Diagnostic Centres:2
Growth Outlook
Growth is driven by the expansion of its oncology network and the scaling of fertility services under the Milann brand. The company continues to leverage its centres of excellence to capture increasing demand for specialised tertiary care in India.
Key Risks
- Regulatory Risk. Changes in government healthcare policies or price caps on medical procedures could adversely impact profit margins.
- Operational Concentration. The company's heavy reliance on oncology services makes it vulnerable to shifts in cancer treatment protocols or competition in the specialised care segment.
- Talent Retention. The ability to attract and retain highly skilled oncologists and medical specialists is critical for maintaining service quality and reputation.
- Capital Intensity. Maintaining and upgrading advanced medical diagnostic and treatment equipment requires significant ongoing capital expenditure.
Start your research today
Unlock AI insights, financials, peers and live data on Healthcare Global Enterprises Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,627 Cr
TTM · consolidated
NET PROFIT
₹33 Cr
TTM · consolidated
EPS
₹1.55
TTM · consolidated
RETURN ON EQUITY
3.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
7.7%
TTM · consolidated
P/E
451.7x
Q1 FY27 · consolidated
EV/EBITDA
21.2x
Q1 FY27 · consolidated
EBITDA MARGIN
19.4%
TTM · consolidated
NET PROFIT MARGIN
2.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.7x
Q1 FY27 · consolidated
Peers · Hospital
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Healthcare Global Enterprises Ltd.HCG | ₹10,454 Cr | 451.74 | 21.21 | 13.8% | 19.4% | 3.0% | 7.7% | +0.7% |
Rainbow Childrens Medicare LtdRAINBOW | ₹14,698 Cr | 51.48 | 23.97 | 18.3% | 33.6% | 18.6% | 18.7% | -4.8% |
Park Medi WorldPARKHOSPS | ₹12,364 Cr | — | — | — | 27.0% | — | — | — |
Yatharth Hospital & Trauma Care Services LimitedYATHARTH | ₹9,550 Cr | 52.72 | 28.25 | 44.0% | 25.4% | 10.2% | 12.7% | +28.9% |
Jupiter Life Line Hospitals Ltd.JLHL | ₹9,391 Cr | 10.01 | 25.62 | 18.2% | 24.7% | 12.8% | 14.6% | -80.1% |
Kovai Medical Center & Hospital LimitedKOVAI | ₹6,634 Cr | 27.14 | 14.86 | 15.7% | 29.4% | 21.4% | 22.6% | -2.5% |
As of Q1 FY27
Financials
Healthcare Global Enterprises Ltd.
NSE: HCG · Hospital
Snapshot
Unlock Healthcare Global Enterprises Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
HealthCare Global Enterprises Limited is a specialised healthcare provider primarily focused on comprehensive cancer care, including diagnosis, radiation therapy, medical oncology, and surgery. The company also operates fertility clinics under the Milann brand and maintains a network of multi-specialty hospitals and diagnostic centres across India and Africa.
Business Model
The company generates revenue through the provision of specialised medical services, including oncology treatments, fertility procedures, and multi-specialty hospital care. It operates through a combination of owned centres, day-care facilities, and management contracts for hospital operations.
- Cancer Centres:23
- Diagnostic Centres:2
Growth Outlook
Growth is driven by the expansion of its oncology network and the scaling of fertility services under the Milann brand. The company continues to leverage its centres of excellence to capture increasing demand for specialised tertiary care in India.
Key Risks
- Regulatory Risk. Changes in government healthcare policies or price caps on medical procedures could adversely impact profit margins.
- Operational Concentration. The company's heavy reliance on oncology services makes it vulnerable to shifts in cancer treatment protocols or competition in the specialised care segment.
- Talent Retention. The ability to attract and retain highly skilled oncologists and medical specialists is critical for maintaining service quality and reputation.
- Capital Intensity. Maintaining and upgrading advanced medical diagnostic and treatment equipment requires significant ongoing capital expenditure.
Start your research today
Unlock AI insights, financials, peers and live data on Healthcare Global Enterprises Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,627 Cr
TTM · consolidated
NET PROFIT
₹33 Cr
TTM · consolidated
EPS
₹1.55
TTM · consolidated
RETURN ON EQUITY
3.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
7.7%
TTM · consolidated
P/E
451.7x
Q1 FY27 · consolidated
EV/EBITDA
21.2x
Q1 FY27 · consolidated
EBITDA MARGIN
19.4%
TTM · consolidated
NET PROFIT MARGIN
2.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.7x
Q1 FY27 · consolidated
Peers · Hospital
As of Q1 FY27